Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,935 total articles
Innodata (INOD) has re-emerged as one of the cleaner pure plays in data-engineering for AI: accelerating revenue, wider gross margins and large new contract wins underpin an upgraded long stance. The stock is expensive today at $55.64, but the company’s 40%+ guidance and a 49% adjusted gross margin show the story is moving from promise to proof. Th…
Oracle is down roughly 55% from its 2025 highs and trading at $159.70 after a period of heavy data-center spending that pushed free cash flow negative. Fundamentals remain solid - 17% revenue growth to ~$67B, 36% net income growth, and 75% cloud infrastructure growth - while valuation metrics (P/E ~27, EV/EBITDA ~17.5) look reasonable for a busines…
Rocket Companies (RKT) is trading near $14 and looks attractive as a mid-term trade. Market-share gains across direct and partner channels, activist interest and a clear path to cost and cross-sell synergies support upside to $18 over the next 45 trading days, while a $12.10 stop limits downside if housing stress re-intensifies.
Nano Labs (NA) is a micro-cap semiconductor and distributed computing play that combines chip design, AI hardware and a meaningful crypto treasury. With a market cap of roughly $51.3M and a 70,000 BNB reserve, the company offers an asymmetric payoff: a successful execution of its AI-Web3 strategy or a rebound in BNB could re-rate the stock, while c…
Bristol Myers Squibb is trading near its 52-week high after sustained strength in newer franchises, notably Camzyos, which grew 74% YoY to $729M in H1 2026. Fundamentals - including a $136.5B market cap, $11.44B free cash flow and a 3.76% dividend yield - and improving technicals argue for a mid-term long. This trade lays out an entry at $66.80, st…
Qualcomm is a high-quality semiconductor franchise trading at a reasonable multiple with strong cash generation and a credible pathway into AI and PCs. The trade is a long-term buy for investors willing to accept near-term handset weakness and execution risk on data-center ambitions. Entry, stop and target provided for a 180-trading-day horizon.
AST SpaceMobile is a speculative long with a concrete catalyst schedule. I’m initiating a long position at $62.30 with a $92 target and a $48 stop, banking on the company converting carrier partnerships and a planned constellation deployment in early 2027 to accelerate revenue and compress an extreme valuation.
Hershey has weathered a commodity storm and kept pricing power intact. With cocoa moving lower, margin recovery is realistic, consensus EPS growth still elevated, and the shares offer a 3.31% cash yield. Technicals look oversold and short interest remains elevated — conditions that favor a measured long. Trade plan included for mid-term (45 trading…
Interactive Brokers (IBKR) is benefiting from strong account growth, rising DARTs and a 49% surge in margin loans, but it trades at a premium multiple and shows short-term technical fatigue. The trade: selectively buy weakness around $86.00 with a $105.00 target over a mid-term 45 trading day horizon and a $79.00 stop. Risk/reward is asymmetric if …
Northwest Natural (NWN) is a compact, dividend-rich regulated gas and water distributor that offers a 4%+ yield, reasonable valuation and visible catalysts (rate cases, acquisitions, RNG growth). The business has predictable cash flows and a long history of dividend increases; the main near-term concerns are leverage and negative free cash flow. Th…
Micron is trading around $1,015 after a sharp multi-month run. Fundamentals support further gains: $1.15T market cap, $44.69 EPS, strong ROE and $26.2B in free cash flow. This trade idea lays out an actionable long with entry, stop and target for a long-term (180 trading days) horizon while calling out the main risks, including Chinese competition …
BioAge (BIOA) is a clinical-stage biotech with an oral NLRP3 inhibitor, BGE-102, showing strong Phase 1 biomarker moves. Topline Phase 2 cardiovascular risk data are due in H2 2026. The stock is trading at $9.59 with a market cap of ~$440M and cash runway into 2029. This trade targets a rebound into the low teens and beyond if Phase 2 confirms the …
CGI (GIB) trades on a reasonable multiple with buyback-driven EPS support and a manageable technical setup. Enter a mid-term long to capture a rebound toward the $86 level while limiting downside with a $68 stop. Watch for buyback commentary and quarterly results to confirm the thesis.
Bitcoin's structural scarcity and persistent accumulation create a genuine supply shortage, supporting upside. At the same time, liquidity is fragile: concentrated exchange flows, large derivatives positions, and sentiment-driven exits can trigger fast, deep drawdowns. This trade idea offers a mid-term (45 trading days) long with a clear entry, sto…
AeroVironment sits at the intersection of a near-term corporate catalyst and an industry tailwind. With earnings on 09/09/2026 and renewed geopolitical attention on drones and munitions, the setup favors a short-term long trade into the report. The company’s valuation and weak recent price action create asymmetric upside if guidance or revenue surp…
Alarm.com is a leader in cloud-based connected property services with recurring SaaS revenue, recent analyst upside and accelerating product-led innovation. At a $2.77B market cap, the stock trades with modest P/E but high P/FCF, leaving room for upside if subscriber momentum and margin leverage continue. This trade idea lays out an actionable long…
Comstock Resources has quietly restructured key pieces of its balance sheet through a trio of transactions that together could cut pro forma net debt materially and fund near-term Haynesville drilling. At $15.27 the stock is trading on low multiples and high optionality. This trade idea lays out an entry, stop and target for a long stance over the …
Vertex's Casgevy commercialization is now concrete proof that CRISPR/Cas9 can translate to an approved, revenue-generating therapy. That validation materially derisks CRISPR Therapeutics' platform and increases the plausibility of a strategic acquisition at a meaningful premium. We lay out a long trade with entry at $55.99, a stop at $47.50 and a t…
CoreWeave has quietly evolved from a GPU rental shop into a vertically integrated AI compute platform. The trade here is a core long: buy on constructive pullbacks and hold for platform monetization, capacity densification and enterprise adoption. Entry $40.00, stop $28.00, target $76.00 over a long-term (180 trading days) horizon.
Nebius (NBIS) has been a market favorite in 2026 as AI build-out drives outsized demand for GPU cloud capacity. The stock's recent surge and strong volumes create a disciplined swing opportunity: enter on a measured pullback to technical support, target the prior high near $300, and place a tight stop below key moving averages. The risk-reward favo…
Broadcom posted an explosive quarter driven by AI semiconductors, yet the stock pulled back after cautious guidance. This trade idea buys the post-earnings dip with a defined stop and a mid-term horizon, balancing the upside from continued hyperscaler capex against stretched valuation metrics and concentration risks.
JPMorgan (JPM) is profitable at scale - EPS near $24 and ROE ~17% - yet capital and cash-flow signals create an asymmetric downside over the next 45 trading days. This trade idea outlines a defined short with entry at $360.00, target at $336.00 and stop at $372.00 driven by deteriorating capital cushions, negative free cash flow, and weakening tech…
Ultra Clean (UCTT) has seen a dramatic run and a sizeable pullback. The semiconductor-led demand picture is constructive, but the stock trades at elevated multiples vs. current profitability and has negative free cash flow. This trade idea lays out an entry at $71.00, a stop at $63.00 and a primary target of $95.00 for a mid-term position (45 tradi…
Lufax is trading like a distressed credit play despite an implied book value that dwarfs its $2.44B market cap. With heavy short interest, ongoing litigation and audit scrutiny, the stock is volatile. This trade targets a first recovery to $1.55 while risking a controlled stop at $1.00 — a speculative, data-driven long sized for a mid-term (45 trad…
Hurco's latest quarter shows a broadening industrial recovery: orders are up, Americas end market strength is clear, and gross margins ticked higher even as sales dipped. With $48M in cash, no debt, and an attractive EV/sales multiple, the risk/reward favors a medium-risk long trade around $23, targeting $26 over the next 45 trading days and a stop…
